Eikon is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases.
Eikon Therapeutics is pioneering a new method of drug discovery based on tracking and measuring movement of individual proteins in live cells.
Eikon was co-founded in 2019 by Eric Betzig, Luke Lavi, Robert Tjian, aand Xavier Darzacq. The company is headquartered in Hayward, CA.
Eikon has developed proprietary, purpose-built platforms that permit precise characterization of protein interactions in living cells with exceptional spatial and temporal resolution. These tools provide a means of examining fleeting but essential interactions among individual protein molecules in living cells.
Eikon uses proprietary, purpose-built microscopes coupled with robotic cell manipulation systems and high-performance computing to visualize the movement of selected proteins in living cells.
Eikon has engineered a fully automated system that can run thousands of SPT assays and process the resulting data each day, enabling high throughput screening of SPT biology.
Eikon is backed by The Column Group, T. Rowe Price, General Catalyst, Foresite Capital, Innovation Endeavors, Lux Capital, Horizons Ventures, UC Investments, Stepstone Group, Schroders Capital, and others. The company raised $517.8M in Series B round on Jan 06, 2022. This brings Eikon's total funding to $665.8M to date.